Home › NDC Lookup › Ingredients › Methimazole › 33342-0336-11
Methimazole 10 mg Tablet, Bottle of 100 — NDC 33342-0336-11 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 33342-0336-11: Methimazole 10 mg Tablet, Bottle of 100

by Macleods Pharmaceuticals Limited

This is a package of 100 tablets of Methimazole 10 mg Tablet from Macleods Pharmaceuticals Limited, first listed with the FDA May 2023 and currently FDA-listed; retail pharmacies pay about $0.1236 per tablet (NADAC). It is the main listing for this product, which comes in 3 package sizes.

🏷️ FDA NDC (as labeled) 33342-336-11 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.1236 NADAC Per package$12.36 / 100 tablets Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.2307/unit · Part D plans $0.1781/unit — full pricing hub ↓
Main listing for product 33342-336 · Also comes in: 100 tablets 33342-336-12 1000 tablets 33342-336-44
Rx only Generic FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 33342-336-11 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
33342 labeler · 336 product · 11 package
Package marketed since
May 24, 2023
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC)
0333342335111, 0333342335449, 0333342336446, 0333342336118
Medicaid fills, this package
14,945 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 33342-336-11
Product NDC 33342-336
11-digit billing NDC 33342033611
NCPDP billing unit EA — each (per item)
RxCUI 197941, 197942
UNII 554Z48XN5E
UPC 0333342335111, 0333342335449, 0333342336446, 0333342336118
Application # ANDA209827
SPL Set ID 6f08df05-cc29-45ef-8f6e-12272bfbb0d7
Established class (EPC) Thyroid Hormone Synthesis Inhibitor
Mechanism of action Thyroid Hormone Synthesis Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2023-05-24
Route ORAL
Dosage form TABLET
Substance METHIMAZOLE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 28300010000310
GCN Seq No 006674
GCN 26400
HICL code 002855
Ingredient (HICL) Methimazole
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P3
Therapeutic class — intermediate (HIC2) Drugs Affecting Thyroid Function
HIC3 code P3L
Therapeutic class — specific (HIC3) Antithyroid Preparations
AHFS code 68:36.08.00
AHFS class Antithyroid Agents
FDB label name METHIMAZOLE 10 MG TABLET
FDB brand name Methimazole
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 006674
  • GCN: 26400
  • GPI-14 (Medi-Span): 28300010000310
  • HICL (First Databank): 002855
  • AHFS class code: 68:36.08.00
  • RxCUI (RxNorm): 197941
Why two NDCs? The FDA registers this code as 33342-336-11 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 33342-0336-11. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Thyroid Hormone Synthesis Inhibitor class.

Pharmacologic class Thyroid Hormone Synthesis Inhibitor
Drug family (ATC) Sulfur-containing imidazole derivatives
How it works Thyroid Hormone Synthesis Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name METHIMAZOLE 10 MG TABLET Ingredient Methimazole
📖 What it is MedlinePlus · NLM

Methimazole is used to treat hyperthyroidism, a condition that occurs when the thyroid gland produces too much thyroid hormone. It is also taken before thyroid surgery or radioactive iodine therapy. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats hyperthyroidism, meaning an overactive thyroid, from Graves’ disease or toxic multinodular goiter. It is used when surgery or radioactive iodine is not a good option. It...
  • You swallow the tablets by mouth. The daily amount is usually split into 3 doses about 8 hours apart. Follow your prescriber’s directions and the label on your bottle.
  • Call right away if you have a fever or sore throat, since that can be a sign of a dangerous drop in white blood cells. Also call for yellowing of the skin or eyes, itching, upper r...
  • What side effects should I call my doctor about?
📖 Read our full Methimazole guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.124 $12.36 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2307 $23.07 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.1781 $17.81 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2024 Jul 2025 Mar 2026 Nov 2026 $0.137 $0.112
▲ Up 11% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
33342-0336-11 You're viewing this Main listing 100 TABLET in 1 BOTTLE $0.1236 / ea $12.36 2023-05-24 — Active
33342-0336-12 33342-336-12 10 BLISTER PACK in 1 CARTON / 10 TABLET in 1 BLISTER PACK — — 2023-05-24 — Active
33342-0336-44 33342-336-44 1000 TABLET in 1 BOTTLE — — 2023-05-24 — Active

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 33342-0336-12?
Both are Methimazole 10 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 33342-0336-12 is the 100 tablets package.
What NDC number is used to bill for this package of Methimazole 10 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Methimazole 10 mg 00832-6073-11 Upsher-Smith 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 11788-0012-01 AiPing 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 23155-0071-01 Heritage 100 tablets $0.124 AB Availability likely —
Methimazole 10 mgthis 33342-0336-11 Macleods 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 50268-0496-15 AvPAK 50 tablets $0.124 AB Availability likely —
Methimazole 10 mg 60687-0680-01 American 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 64380-0213-01 Strides 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 64980-0265-01 Rising 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 69452-0329-20 Bionpharma 100 tablets $0.124 AB Availability likely —
methimazole 10 mg 72578-0213-01 Viona 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 72603-0316-01 NORTHSTAR 100 tablets $0.124 AB Availability likely —
Methimazole 10 mg 60429-0381-01 Golden 100 tablets — AB FDA listed —
Methimazole 10 mg 62135-0206-01 Chartwell 100 tablets — AB FDA listed —
Methimazole 10 mg 63629-9251-01 Bryant 100 tablets — AB FDA listed —
methimazole 10 mg 67046-1652-03 Coupler 30 tablets — AB FDA listed —
Methimazole 10 mg 68788-4063-01 Preferred 100 tablets — AB FDA listed —
Methimazole 10 mg 68788-8227-01 Preferred 100 tablets — AB FDA listed —
Methimazole 10 mg 70518-1475-00 REMEDYREPACK 30 tablets — AB FDA listed —
Methimazole 10 mg 71335-0883-01 Bryant 30 tablets — AB FDA listed —
Methimazole 10 mg 71335-2218-01 Bryant 30 tablets — AB FDA listed —
Methimazole 10 mg 71335-2349-01 Bryant 30 tablets — AB FDA listed —
Methimazole 10 mg 71335-2906-01 Bryant 100 tablets — AB FDA listed —
Methimazole 10 mg 71335-3027-01 Bryant 180 tablets — AB FDA listed —
Methimazole 10 mg 72162-1803-01 Bryant 100 tablets — AB FDA listed —
Methimazole 10 mg 73190-0085-01 AvKARE 100 tablets — AB FDA listed —
methimazole 10 mg 76483-0083-00 SQUARE 100 tablets — AB FDA listed —
Methimazole 10 mg 82804-0231-30 Proficient 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
Listed with the FDA since
May 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
This is a generic
listed with the FDA
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintT;81
Size8 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Methimazole inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII 7SEV7J4R1U
    A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMacleods Pharmaceuticals Limited
Application holderMACLEODS PHARMACEUTICALS LTD
FDA applicationANDA209827 (ANDA)
Labeler code33342
First marketedMay 2023
Product typeHuman Prescription Drug
Portfolio389 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 43 words ▾

INDICATIONS & USAGE Methimazole is indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy.

⏱️ Dosage and Administration 96 words ▾

DOSAGE & ADMINISTRATION Methimazole is administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals. Adults- The initial daily dosage is 15 mg for mild hyperthyroidism, 30 mg to 40 mg for moderately severe hyperthyroidism, and 60 mg for severe hyperthyroidism, divided into 3 doses at 8-hour intervals.

The maintenance dosage is 5 mg to 15 mg daily. Pediatric - Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.

⛔ Contraindications 19 words ▾

CONTRAINDICATIONS Methimazole is contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

⚠️ Warnings ~2 min read ▾

WARNINGS First Trimester Use of Methimazole and Congenital Malformations Methimazole crosses the placental membranes and can cause fetal harm when administered in the first trimester of pregnancy. Rare instances of congenital defects, including aplasia cutis, craniofacial malformations (facial dysmorphism; choanal atresia), gastrointestinal malformations (esophageal atresia with or without tracheoesophageal fistula), omphalocele and abnormalities of the omphalomesenteric duct have occurred in infants born to mothers who received methimazole in the first trimester of pregnancy.

If methimazole tablets are used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. Because of the risk for congenital malformations associated with use of methimazole in the first trimester of pregnancy, it may be appropriate to use other agents in pregnant women requiring treatment for hyperthyroidism. If methimazole tablets is used, the lowest possible dose to control the maternal disease should be given.

Agranulocytosis Agranulocytosis is a potentially life-threatening adverse reaction of methimazole therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of agranulocytosis, such as fever or sore throat. Leukopenia, thrombocytopenia, and aplastic anemia (pancytopenia) may also occur.

The drug should be discontinued in the presence of agranulocytosis or aplastic anemia (pancytopenia), and the patient’s bone marrow indices should be monitored. Liver Toxicity Although there have been reports of hepatotoxicity (including acute liver failure) associated with methimazole, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction (anorexia, pruritus, right upper quadrant pain, etc) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellular integrity (ALT, AST).Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.

Hypothyroidism Methimazole can cause hypothyroidism necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal goiter and cretinism when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy (see PRECAUTIONS, Pregnancy).

Vasculitis Cases of vasculitis resulting in severe complications have been reported in patients receiving methimazole therapy. These cases of vasculitis include: leukocytoclastic cutaneous vasculitis, acute kidney injury and glomerulonephritis, alveolar/pulmonary hemorrhage, CNS vasculitis, and neuropathy.Most cases were associated with anti-neutrophilic cytoplasmic antibodies (ANCA)-positive vasculitis. In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis.

If vasculitis is suspected, discontinue therapy and initiate appropriate intervention

🤒 Adverse Reactions 144 words ▾

ADVERSE REACTIONS Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoieses (agranulocytosis, granulocytopenia, thrombocytopenia, and aplastic anemia), drug fever, a lupus-like syndrome, insulin autoimmune syndrome (which can result in hypoglycemic coma), hepatitis (jaundice may persist for several weeks after discontinuation of the drug), periarteritis, and hypoprothrombinemia. Nephritis occurs very rarely. There have been postmarketing case reports of acute pancreatitis.

There are reports of a vasculitis, often associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA), resulting in severe complications (see WARNINGS). Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesia, loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, and lymphadenopathy. To report SUSPECTED ADVERSE REACTIONS , contact Macleods Pharma USA, Inc. at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🔄 Drug Interactions 122 words ▾

Drug Interactions Anticoagulants (oral) - Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents - Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid. Digitalis glycosides - Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.

Theophylline - Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.

🤰 Pregnancy 203 words ▾

Pregnancy (See WARNINGS) If methimazole is used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. In pregnant women with untreated or inadequately treated Graves’ disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism. Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy.

In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery. Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy during organogenesis.

Given the potential maternal adverse effects of propylthiouracil (e.g., hepatotoxicity), it may be preferable to switch from propylthiouracil to methimazole for the second and third trimesters.

🧒 Pediatric Use 36 words ▾

Pediatric Use Because of postmarketing reports of severe liver injury in pediatric patients treated with propylthiouracil, methimazole is the preferred choice when an antithyroid drug is required for a pediatric patient. (See DOSAGE AND ADMINISTRATION .)

🆘 Overdosage 127 words ▾

OVERDOSAGE Signs and Symptoms Symptoms may include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancytopenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.

No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or death. Treatment To obtain up-to-date information about the treatment of overdose, a good resource is the certified RegionalPoison ControlCenter. In managing overdosage, consider the possibility of multiple drug overdoses, interaction among drugs, and unusual drug kinetics in the patient.

In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s medical status.

🧬 Clinical Pharmacology 71 words ▾

CLINICAL PHARMACOLOGY Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and tri-iodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection. Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.

📦 How Supplied / Storage and Handling 167 words ▾

HOW SUPPLIED Methimazole tablets, USP 5 mg - white to off-white, round, flat-faced, bevelled-edged tablets, debossed with “T and 80”separated by breakline on one side and plain on the other side. They are available in: Bottles of 100 NDC 33342-335-11 Bottles of 1000 NDC 33342-335-44 Cartons of 100 (10 x 10 unit-dose blister) NDC 33342-335-12 Methimazole tablets, USP 10 mg - white to off-white, round, flat-faced, bevelled-edged tablets, debossed with “T and 81”separated by breakline on one side and plain on the other side.

They are available in: Bottles of 100 NDC 33342-336-11 Bottles of 1000 NDC 33342-336-44 Cartons of 100 (10 x 10 unit-dose blister) NDC 33342-336-12 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container. Manufactured for: Macleods Pharma USA, Inc.

Princeton, NJ 08540 Manufactured by: Macleods Pharmaceuticals Ltd. At Oxalis Labs Baddi, Himachal Pradesh, INDIA OR Macleods Pharmaceuticals Ltd. Baddi, Himachal Pradesh-174101 INDIA Issue: September 2025

📋 Description 88 words ▾

DESCRIPTION Methimazole (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from the drugs of the thiouracil series primarily because it has a 5-instead of a 6-membered ring. Methimazole tablet, USP contains 5 mg or 10 mg (43.8 or 87.6 μmol) methimazole, an orally administered antithyroid drug.

Each tablet also contains lactose monohydrate, pregelatinised starch, talc, and magnesium stearate. The molecular weight is 114.17, and the molecular formula is C 4 H 6 N 2 S.The structural formula is as follows: str

💬 Information for Patients 73 words ▾

Information for Patients Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyroid drug, they should contact their physician immediately about their therapy. Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole. Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis (see WARNINGS and ADVERSE REACTIONS).

⚠️ Precautions ~3 min read ▾

PRECAUTIONS Genral Patients who receive methimazole should be under close surveillance and should be cautioned to report immediately any evidence of illness, particularly sore throat, skin eruptions, fever, headache, or general malaise. In such cases, white-blood-cell and differential counts should be obtained to determine whether agranulocytosis has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause agranulocytosis.

Information for Patients Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyroid drug, they should contact their physician immediately about their therapy. Inform patients that cases of vasculitis resulting in severe complications have occurred with methimazole. Inform patients to promptly report symptoms that may be associated with vasculitis including new rash, hematuria or decreased urine output, dyspnea or hemoptysis (see WARNINGS and ADVERSE REACTIONS).

Laboratory Tests Because methimazole may cause hypoprothrombinemia and bleeding, prothrombin time should be monitored during therapy with the drug, especially before surgical procedures. Thyroid function tests should be monitored periodically during therapy. Once clinical evidence of hyperthyroidism has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of methimazole should be employed.

Drug Interactions Anticoagulants (oral) - Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents - Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid. Digitalis glycosides - Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.

Theophylline - Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2 year study, rats were given methimazole at doses of 0.5, 3, and 18 mg/kg/day. These doses were 0.3, 2, and 12 times the 15 mg/day maximum human maintenance dose (when calculated on the basis of surface area).Thyroid hyperplasia, adenoma, and carcinoma developed in rats at the two higher doses.

The clinical significance of these findings is unclear. Pregnancy (See WARNINGS) If methimazole is used during the first trimester of pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus. In pregnant women with untreated or inadequately treated Graves’ disease, there is an increased risk of adverse events of maternal heart failure, spontaneous abortion, preterm birth, stillbirth and fetal or neonatal hyperthyroidism.

Because methimazole crosses placental membranes and can induce goiter and cretinism in the developing fetus, hyperthyroidism should be closely monitored in pregnant women and treatment adjusted such that a sufficient, but not excessive, dose be given during pregnancy. In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction of dosage may be possible. In some instances, anti-thyroid therapy can be discontinued several weeks or months before delivery.

Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use an alternative anti-thyroid medication in pregnant women requiring treatment for hyperthyroidism, particularly in the first trimester of pregnancy during organogenesis. Given the potential maternal adverse e… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers 59 words ▾

Nursing Mothers Methimazole is present in breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants who are nursed by mothers receiving treatment with methimazole. Monitor thyroid function at frequent (weekly or biweekly) intervals.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 65 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2 year study, rats were given methimazole at doses of 0.5, 3, and 18 mg/kg/day. These doses were 0.3, 2, and 12 times the 15 mg/day maximum human maintenance dose (when calculated on the basis of surface area).Thyroid hyperplasia, adenoma, and carcinoma developed in rats at the two higher doses. The clinical significance of these findings is unclear.

📄 Package Label / Principal Display Panel 112 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Rx only Methimazole Tablets, USP 5 mg NDC: 33342-335-11 container 100's Tablets Oxalis- Rx only Methimazole Tablets, USP 5 mg NDC: 33342-335-11 container 100's Tablets Baddi- Rx only Methimazole Tablets, USP 5 mg NDC: 33342-335-44 container 1000's Tablets Rx only Methimazole Tablets, USP 5 mg NDC: 33342-335-12 Carton 100's Tablets Rx only Methimazole Tablets, USP 10 mg NDC: 33342-336-11 container 100's Tablets Oxalis- Rx only Methimazole Tablets, USP 10 mg NDC: 33342-336-11 container 100's Tablets Baddi- Rx only Methimazole Tablets, USP 10 mg NDC: 33342-336-44 container 1000's Tablets Rx only Methimazole Tablets, USP 10 mg NDC: 33342-336-12 Carton 100's Tablets methimazole-5mg-container-100.jpg 565 methimazole-5mg-container-1000.jpg methimazole-5mg-carton-100.jpg methimazole-10mg-container-100.jpg 505 methimazole-10mg-container-1000.jpg methimazole-10mg-carton-100

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
14.9K
Units reimbursed last 4 qtrs
1.2M
Gross reimbursed last 4 qtrs
$272.6K
Avg / prescription
$18.24
Avg / unit
$0.2307
Latest quarter Q1 2026
3.2KRx
Medicaid pays / ea
$0.2307
gross reimbursed
vs
NADAC / ea
$0.1236
acquisition cost
=
Spread
+$0.1071
+87% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
34% FFS 66% MCO
Fee-for-service · 5,121 Rx Managed care · 9,824 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 9,471 units · 165 per 100k residents MN Wisconsin: 8,751 units · 148 per 100k residents WI Michigan: 43,143 units · 430 per 100k residents MI New York: 242,367 units · 1,238 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 9,143 units · 216 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 2,230 units · 69.5 per 100k residents IA Illinois: 55,809 units · 445 per 100k residents IL Indiana: 82,245 units · 1,199 per 100k residents IN Ohio: 72,806 units · 618 per 100k residents OH Pennsylvania: 165,718 units · 1,279 per 100k residents PA New Jersey: 81,542 units · 878 per 100k residents NJ Massachusetts: no data reported MA California: 187,846 units · 482 per 100k residents CA Utah: no data reported UT Colorado: 12,028 units · 205 per 100k residents CO Nebraska: 900 units · 45.5 per 100k residents NE Missouri: 26,009 units · 420 per 100k residents MO Kentucky: 4,436 units · 98.0 per 100k residents KY West Virginia: 13,854 units · 783 per 100k residents WV Virginia: 21,952 units · 252 per 100k residents VA Maryland: 80,856 units · 1,308 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: 2,610 units · 85.1 per 100k residents AR Tennessee: no data reported TN North Carolina: 2,700 units · 24.9 per 100k residents NC South Carolina: no data reported SC Delaware: 2,865 units · 278 per 100k residents DE Oklahoma: 8,440 units · 208 per 100k residents OK Louisiana: 19,381 units · 424 per 100k residents LA Mississippi: 931 units · 31.7 per 100k residents MS Alabama: no data reported AL Georgia: 558 units · 5.1 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 7,946 units · 26.0 per 100k residents TX Florida: no data reported FL
Units reimbursed · per 100k residents
5.11,308
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Maryland 1,308 /100k
2 Pennsylvania 1,279 /100k
3 New York 1,238 /100k
4 Indiana 1,199 /100k
5 New Jersey 878 /100k
6 West Virginia 783 /100k
7 Ohio 618 /100k
8 California 482 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page33342-0336-11 15,508 Rx · $283,527
100 tablets33342-0336-12 No Medicaid data
1000 tablets33342-0336-44 No Medicaid data
Drug total (last 4 qtrs): 15,508 Rx · 1,223,494 units · $283,527 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Methimazole — the program that covers self-administered drugs. 10 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Methimazole. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.92M
Claims incl. refills
257.2K
Beneficiaries
179.3K
Spend / beneficiary
$16.29
Spend / claim
$11.35
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Methimazole — the ingredient across all brands.

Top reported reactions

Fatigue445
Hyperthyroidism407
Nausea381
Diarrhoea335
Headache330
Pain310
Dizziness306

Age at onset

Neonate56
Infant11
Child16
Adolescent35
Adult798
Elderly594

Reporter sex

7,805 reports
Male · 28%
Female · 72%
Unknown · 0%

Serious outcomes

Hospitalization2,870
Life-threatening574
Death304
Disabling210
Reports over time (by year) — tap or hover for the count & year
2020 2022 2024 2026 996 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.